Ivy Center at SNO

The Ivy Brain Tumor Center announced that the first patient has been dosed in the pivotal Phase 3 Gliofocus Study. Gliofocus is an open-label, randomized Phase 3 trial that will compare the efficacy of niraparib, a PARP1/2 selective inhibitor, to temozolomide head-to-head in adult patients with newly diagnosed MGMT-unmethylated glioblastoma.

Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, has been named the 2024 Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association. This prestigious honor recognizes Dr. Sanai’s pioneering efforts and unwavering dedication to advancing new therapies for brain tumor patients, breaking new ground in the fight against this challenging disease.

The Ivy Brain Tumor Center at Barrow Neurological Institute will present updated study results and a special session on clinical trial design at the 19th Meeting of the European Association of Neuro-Oncology (EANO), which will take place in Glasgow, Scotland, October 17-20, 2024.

The Ivy Brain Tumor Center has released promising Phase 0/2 clinical trial results for niraparib, showing a significant improvement in overall survival for newly diagnosed glioblastoma patients, with survival times nearly doubling to 20.3 months compared to standard care. These findings will be presented at the 2024 ASCO Annual Meeting. Encouraged by these results, GSK is supporting the initiation of a global Phase 3 trial to further evaluate niraparib versus standard care.